“…Similarly, nonspecific clinical phenotypes characterized the Fabry disease in childhood, with a high rate of misdiagnosis and damage in adulthood. Only in-depth screening programs of high-risk groups and the creation of networks between different specialties could improve diagnosis and therapy management [12,13]. In this context, the long-term effect of enzyme replacement therapy may delay the progression of the disease in Fabry patients [14].…”